



TFW 1639  
\$

Attorney Docket No. P24,375-A USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTORS: Kenneth Iain Cummings and  
Zebunnissa Ramtoola

APPLICATION NO. 09/510,560 Examiner: P. Ponnaluri

FILED: February 22, 2000 Art Unit: 1639

CONFIRMATION NO.: 3011

TITLE: SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER

(Attorney Docket No. P24,375-A USA)

---

Certificate of Mailing

I certify that this document and fee is being deposited with the U.S. Postal Service as first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 10, 2005.

  
Dorothy M. Musgreave

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Supplemental Information Disclosure Statement  
Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98

Sir:

Pursuant to Applicant's duty of disclosure set forth in 37 CFR §§ 1.56, 1.97 and 1.98, the following information is disclosed to aid the Examiner in his or her examination of the application. The inclusion of information in this Supplemental Disclosure Statement and as set forth on the attached Forms PTO-1449 is not necessarily a concession that such information is prior art to the present invention or that such information is in an art area analogous to the present invention. Copies of the publications listed on the attached Forms PTO-1449 are submitted herewith.

11/15/2005 FNETEKI1 00000023 09510560

01 FC:1806

180.00 0P


Attorney Docket No. P24,375-A USA

It is respectfully requested that the Examiner initial Forms PTO-1449 and return a copy of same upon consideration of these publications.

A PTO-238 Credit Card Form is enclosed for the required fee for this Supplemental Information Disclosure Statement

Respectfully submitted,

Date November 10, 2005



Joshua R. Slavitt  
Reg. No. 40,816  
Synnestvedt & Lechner LLP  
2600 Aramark Tower  
1101 Market Street  
Philadelphia, PA 19107-2950  
(215) 923-4466

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
**P24,375-A USA**

In Re Application Of: **Kenneth Iain Cummings and  
Zebunnissa Ramtoola**

Application No.

09/510,566

Filing Date

February 22, 2000

Examiner

P. Ponnaluri

Customer No.

Group Art Unit

1639

Confirmation No.

3011

Title:

**SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER**

Address to:

**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

**37 CFR 1.97(b)**

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**


☒ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
P24,375-A USA

In Re Application: **Kenneth Iain Cummings and**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/510,560	February 22, 2000	P. Ponnaluri		1639	3011



**SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. **19-5425** as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☐ Charge any additional fee required.
- ☒ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**\*This certificate may only be used if paying by deposit account.**

Signature

**Joshua R. Slavitt**

**Reg. No. 40,816**

**Synnestvedt & Lechner LLP**

**2600 Aramark Tower**

**1101 Market Street**

**Philadelphia, PA 19107**

**Telephone No. (215) 923-4466**

**Facsimile No. (215) 923-2189**

CC:

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

**November 10, 2005**


\_\_\_\_\_  
(Date)

Signature of Person Mailing Correspondence

**Dorothy M. Musgreave**

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

Dated: **November 10, 2005**



## Form PTO-1449 Modified

List of Patents and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
P24,375-A USA

Application No.  
09/510,560

Applicant(s) Kenneth Iain Cummings and  
Zebunnissa Ramtoola

Filing Date  
February 22, 2000


Group

## U.S. PATENT DOCUMENTS

Examiner Initials		Document No.	Date	Name	Class	Subclass
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document No.	Date	Country	Translation	
					Yes	No
	B1	(11) 63119	21-11-1989	Ireland		
Examiner			Date Considered			



<b>Form PTO-1449</b> <b>Modified</b>  <b>List of Patents and Publications</b> <b>Cited by Applicant</b> <b>(Use several sheets if necessary)</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Docket No.</b> P24,375-A USA	<b>Application No.</b> 09,510,560
	<b>Applicant(s)</b> Kenneth Iain Cummings and Zebunnissa Ramtoola	
	<b>Filing Date</b> February 22, 2000	<b>Group</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	AA	Aungst, Bruce K. et al., Enhancement of the Intestinal Absorption of Peptides and Non-Peptides, Journal of Controlled Release 41 (1996) pgs. 19-31.
	AB	Palin, K. J. et al., The Oral Absorption of Cefoxitin from Oil and Emulsion Vehicles in Rats, International Journal of Pharmaceutics, 33 (1986) pgs. 99-104.
	AC	Tomita, M. et al., Enhancement of Colonic Drug Absorption by the Paracellular Permeation Route, Pharmaceutical Research Vol. 5, No. 6, (1988), pgs. 341-346.
	AD	Murakami, M. et al., Effect of Oleic Acid Vesicles on Intestinal Absorption of Carboxyfluorescein in Rats, Pharmaceutical Research, Vol. 3, No. 1, 1986, pgs. 35-40.
	AE	Muranushi, N. et al., The Effects Of Fatty Acids And Their Derivatives On The Intestinal Absorption Of Insulin In Rats, Drug Development and Industrial Pharmacy, 19(8), pgs. 929-941 (1993)
	AF	Tomita, M. et al., Differences in the Enhancing Effects of Sodium Caprate on Colonic and Jejunal Drug Absorption, Pharmaceutical Research, Vol. 9, No. 5, 1992, pgs. 648-653.
	AG	Tomita, M. et al., Enhancement of Colonic Drug Absorption by the Transcellular Permeation Route, Pharmaceutical Research Vol. 5., No. 12 (1988), pgs. 786-789.
	AH	Anderberg, E. K. et al., Sodium Caprate Elicits Dilatations in Human Intestinal Tight Junctions and Enhances Drug Absorption by the Paracellular Route, Pharmaceutical Research Vol. 10, No. 6, 1993, pgs. 857-864.
	AI	Tomita, Mikio, et al., Absorption-Enhancing Mechanism of Sodium Caprate and Decanoylcarnitine in Caco-2 Cells , The Journal of Pharmacology and Experimental Therapeutics, Vol. 272, No. 2, 1995, pgs. 739-743.
	AJ	Sawada, T., et al., Role of Paracellular Pathway in Nonelectrolyte Permeation Across Rat Colon Epithelium Enhanced by Sodium Caprate and Sodium Caprylate, Pharmaceutical Research, Vol. 8, No. 11, 1991, pgs. 1365-1371.
<b>Examiner</b>	<b>Date Considered</b>	